PTGS2 and melanoma: Here, we identified the miR-146a/COX2 axis as playing a critical role in the mechanisms sustaining melanoma resistance; thus, this axis represents a druggable signaling pathway for improving the effects of BRAF/MEKi therapy in melanoma patients.